Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472885 | 0.91 | CHRM1 (0.47) | MAPTEPHX1GAAL3MBTL1EPHX2 | |
| SCHEMBL22472868 | 0.85 | MAPT (0.43) | MAPTEPHX1GAAL3MBTL1EPHX2 | |
| SCHEMBL22472879 | 0.83 | EPHX2 (0.39) | GAAEPHX2SMN1; SMN2KDM4ECHRM1 | |
| SCHEMBL21597906 | 0.77 | CHRM1 (0.49) | MAPTEPHX1GAAL3MBTL1EPHX2 | |
| SCHEMBL22472937 | 0.76 | CHRM1 (0.55) | CHRM1POLB | |
| SCHEMBL22472935 | 0.75 | HPGD (0.47) | SMN1; SMN2POLB | |
| SCHEMBL22472884 | 0.74 | CHRM1 (0.46) | GAAEPHX2SMN1; SMN2CHRM1 | |
| SCHEMBL27176067 | 0.74 | EPHX1 (0.44) | MAPTEPHX1GAAL3MBTL1EPHX2 | |
| SCHEMBL14978890 | 0.72 | CHRM1 (0.65) | MAPTEPHX1GAAL3MBTL1CHRM1 | |
| SCHEMBL14978899 | 0.70 | CHRM1 (0.65) | MAPTEPHX1GAAL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | MAPT 1215/4885EPHX1 978/4885GAA 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.